msmnainar
★    

India,
2013-02-14 09:08
(4447 d 10:31 ago)

Posting: # 10018
Views: 7,921
 

 Add-on study data combining procedure [Two-Stage / GS Designs]

Dear All

Could you confirm how to combine the initial study BE data with add-on study, considering the Healthy Canada regulations.

Request you to address the following queries,
  1. Steps to follow to combine the data from initial study and add-on study
  2. Alpha level to be used
  3. Confidence Interval to be adopted

Thanks and Regards


Edit: Category changed. [Helmut]

Sundar. M
drgunasakaran1
★★  
avatar

2013-02-14 10:54
(4447 d 08:45 ago)

@ msmnainar
Posting: # 10020
Views: 6,790
 

 Add-on study data combining procedure

Dear Mr Msmnainar,

As per Canadian BE guideline, if the study is run with the appropriate size and the standards are not met, the sponsor may add more subjects (a minimum of 12). The same protocol should be used (i.e., same formulations, same lots, same blood sampling times, a minimum number of 12 subjects, etc.). The choice to use this strategy, as with all designs, should be declared and justified a priori.
The level of confidence should be adjusted using the Bonferroni procedure.
The t-value should be that for p=.025 instead of .05.

Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn
msmnainar
★    

India,
2013-02-14 11:39
(4447 d 08:00 ago)

@ drgunasakaran1
Posting: # 10021
Views: 6,865
 

 Add-on study data combining procedure

Hello Dr. Gunasekaran

We have followed all the procedure, as per canadian guideline,

My question is to obtain final results how to combine the both the data.

How to adjust the p value etc.,

Sundar. M
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-02-14 14:32
(4447 d 05:07 ago)

@ msmnainar
Posting: # 10024
Views: 6,789
 

 Ref’s for Methods C/D

Dear Msmnainar,

forget Add-ons (see below). For Methods C and D see:
  • Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. Sequential design approaches for bioequivalence studies with crossover designs. Pharm Stat. 2008;7(4):245–62. doi:10.1002/pst.294.
  • Montague TH, Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ. Additional results for ‘Sequential design approaches for bioequivalence studies with crossover designs’. Pharm Stat. 2011;11(1):8–13. doi:10.1002/pst.483.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
msmnainar
★    

India,
2013-02-14 14:40
(4447 d 04:58 ago)

@ Helmut
Posting: # 10025
Views: 6,750
 

 Ref’s for Methods C/D

Dear HS

Thanks for your valuable information.

Sundar. M
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-02-14 14:22
(4447 d 05:16 ago)

@ drgunasakaran1
Posting: # 10023
Views: 6,957
 

 No more add-ons for submissions in Canada

Dear Dr Gunasakar,

I disagree. Add-on studies (with αadj 0.025) were mentioned in the Jan 2010 draft, but dropped in the final (May 2012) guidance. Only group sequential designs (Pocock 1977; αadj 0.0294) and adaptive designs (Potvin et al. 2008; Method C: αadj 0.05 or 0.0294) are acceptable. Since Pocock’s method was never validated for BE studies (only: superiority testing, parallel design, n1=n2, known variance, Z instead of t) I would only go with Method C (or alternatively with Method D by Montague et al. 2011 if T/R is expected to be 0.9; αadj 0.028).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,695 registered users;
24 visitors (0 registered, 24 guests [including 8 identified bots]).
Forum time: 20:39 CEST (Europe/Vienna)

Do not put your faith in what statistics say until you have carefully
considered what they do not say.    William W. Watt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5